On Friday, Shares of Costco Wholesale Corporation (NASDAQ:COST), gained 0.74% to $141.05.
Costco Wholesale Corporation, stated net sales of $8.7 billion for the month of August, the four weeks ended August 30, 2015, a decrease of one percent from $8.8 billion during the similar period last year.
For the 16-week fourth quarter, the Company stated net sales of $35.0 billion, an improvement of one percent from $34.8 billion in the fourth quarter last year, which ended August 31, 2014.
Costco Wholesale Corporation, together with its auxiliaries, operates membership warehouses. The company offers branded and private-label products in a range of merchandise categories.
Shares of JA Solar Holdings Co., Ltd. (ADR) (NASDAQ:JASO), inclined 0.13% to $8.01, during its last trading session.
JA Solar Holdings Co., declared that Australia’s 70 MW Moree Solar Farm (MSF) has begun to install the batches of solar modules offered by JA Solar since June. As MSF’s exclusive supplier, JA Solar will keep delivering JAP6-315 and JAP6-310 modules to meet all demand of 70 MW modules. Early this year, MSF was acknowledged by IJ Global as the best solar transaction of 2014 in the Asia Pacific region. The award recognizes excellence, achievement and innovation in energy and infrastructure finance.
MSF is located 10 km south of Moree, in northern New South Wales. The project is owned by Fotowatio Renewable Ventures (“FRV”). Project financing totaling $164 million, counting a $102 million grant from the Australian Renewable Energy Agency and $47 million of debt financing from the Clean Energy Finance Corporation, was secured in August 2014, and construction of the farm broke ground in November 2014.
JA Solar Holdings Co., Ltd., together with its auxiliaries, designs, develops, manufactures, and sells photovoltaic solar cells and solar power products based on crystalline silicon technologies.
At the end of Friday’s trade, Shares of Omeros Corporation (NASDAQ:OMER), gained 2.39% to $14.12.
Omeros Corporation, declared additional positive data in the company’s Phase 2 clinical trial of OMS721 for the treatment of thrombotic microangiopathies (TMAs). TMAs are a family of rare, debilitating and life-threatening disorders characterized by excessive thrombi (clots) – aggregations of platelets – in the microcirculation of the body’s organs, most commonly the kidney and brain. OMS721 is Omeros’ lead human monoclonal antibody in its mannan-binding lectin-associated serine protease-2 (MASP-2) program for the treatment of TMAs, counting atypical hemolytic uremic syndrome (aHUS).
The Phase 2 trial is designed to enroll primarily aHUS patients but can also enroll patients with thrombotic thrombocytopenic purpura (TTP) and hematopoietic stem cell transplant (HSCT)-related TMA. The trial has fully enrolled the first and second cohorts and is presently concluding the third and final planned cohort of its dose-ranging stage. In each three-patient cohort, OMS721 is dosed for four weeks. Data from the first (low-dose) cohort were released on February 19, 2015. Recently the company is releasing data from its second (mid-dose) cohort and data to date from its third (high-dose) cohort.
Three patients were treated in the second or mid-dose cohort, two of whom have aHUS and one with TTP. Both patients with aHUS were on renal dialysis preceding to and at the time of study enrollment. Based on the positive data from the mid-dose cohort, the high-dose cohort was initiated and an aHUS patient has already accomplished the study treatment period. No patient with HSCT-related TMA has yet accomplished dosing with OMS721. The data referenced for all patients comprise measures to one week following the last dose.
Omeros Corporation, a biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. It markets Omidria for use during cataract surgery or intraocular lens, or replacement surgery.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
